New updates have been reported about Cala Health.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cala Health has been recognized as the “Best New Neurology Technology Solution” in the 2026 MedTech Breakthrough Awards for its Cala kIQ System, placing the private bioelectronic medicine company among a select group of global health-tech leaders. The award highlights Cala’s wearable neuromodulation platform and its TAPS Therapy, which delivers noninvasive, physician-prescribed stimulation to provide temporary relief of hand tremors in adults with essential tremor.
The recognition reinforces Cala Health’s position in the fast-growing neuromodulation and digital DME market, where it is reshaping at-home, prescription-based care for chronic neurological conditions. With the Cala kIQ device currently the only FDA-cleared wearable delivering effective therapy for action hand tremor in essential tremor and Parkinson’s disease, the award signals increased validation from the medtech community and may enhance payer, clinician, and patient adoption as the company scales access and builds its direct-to-home delivery model.